FDA revised Moderna COVID-19 vaccine EUA to increase the number of vaccine doses available
On Apr. 1, 2021, the U.S. Food and Drug Administration (FDA) announced two revisions regarding the number of…
-
-
Moderna provided storage update and FDA authorization for 15-doses per vial of COVID-19 vaccine
On Apr. 1, 2021, Moderna announced that based on submitted stability data, the U.S. Food and Drug Administration…
-
NIH clinical trial evaluating Moderna COVID-19 variant vaccine began
On Mar. 31, 2021, the National Institutes of Health (NIH) announced that an investigational vaccine designed to protect…
-
T cells recognize recent SARS-CoV-2 variants
On Mar. 30, 2021, the National Institute of Allergy and Infectious Diseases (NIAID) announced that researchers had analyzed…
-
BD announced FDA Emergency Use Authorization for combination COVID-19, flu rapid antigen test
On Mar. 30, 2021, BD (Becton, Dickinson) announced the U.S. Food and Drug Administration (FDA) granted emergency use…
-
CytoDyn’s leronlimab decreased mortality at 14 days by 82% amongst critically Ill COVID-19 patients
On Mar. 30, 2021, CytoDyn announced further results from its CD12 trial of severe-to-critically ill patients with COVID-19….
-
Philippines FDA approved the use of leronlimab to treat a COVID-19 patient
On Mar. 29, 2021, CytoDyn announced that the Republic of the Philippines, Department of Health, Food and Drug…
-
Moderna announced shipment of 100 millionth dose of its COVID-19 vaccine to the U.S. Government
On Mar. 29, 2021, Moderna announced that the Company has shipped the 100-millionth dose of its COVID-19 vaccine…
-
GSK to manufacture Novavax’ COVID-19 vaccine
On Mar. 29, 2021, Novavax, GSK and the UK Government Vaccines Taskforce announced an agreement in principle to…
-
Biden administration announced investment of more than $12 billion to expand COVID-19 testing
On Mar. 25, 2021, the U.S. Department of Health and Human Services (HHS) announced the investment of $10…
-
Positive leronlimab treatment in critically Ill COVID-19 patient published
On Mar. 23, 2021, CytoDyn announced the publication in the Journal of Translational Autoimmunity ‘Case study of a…
-
Existing vaccines may protect against the Brazilian coronavirus variant
On Mar. 19, 2021, scientists at the University of Oxford released pre-print data measuring the level of antibodies…
-
FDA authorized first machine learning-based screening device to identify COVID-19 infection biomarkers
On Mar. 19, 2021, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for the…
-
Incyte announced results from phase 3 DEVENT study evaluating Jakafi as treatment for patients with COVID-19
On Mar. 18, 2021, Incyte announced results from the Phase 3 DEVENT study evaluating the efficacy and safety of…
-
UK and EU regulatory agencies confirmed COVID-19 Vaccine AstraZeneca was safe and effective
On Mar. 18, 2021, AstraZeneca announced that the Medicines and Healthcare products Regulatory Agency (MHRA) and European Medicines…
-
XPhyto announces European approval for 25 minute COVID-19 PCR test
On Mar. 18, 2021, XPhyto and its exclusive German diagnostics development partner, 3a-diagnostics, are pleased to announce the…
-
WHO COVID-19 subcommittee announced safety signals related to AstraZeneca COVID-19 vaccine
On Mar. 17, 2021, the World Health Organization (WHO) reported that the AstraZeneca COVID-19 vaccine (including Covishield) continued…
-
FDA permitted marketing of first SARS-CoV-2 diagnostic test using traditional premarket review process
On Mar. 17, 2021, the U.S. Food and Drug Administration (FDA) granted marketing authorization of the BioFire Respiratory…
-
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Life Science History | Therapeutics | Vaccine
Altasciences partnered with NRC of Canada to qualify quantitative serological assay for detection of SARS-CoV-2 IgG antibodies
On Mar. 17, 2021, Altasciences working with the National Research Council of Canada (NRC), announced that it had…
-
Research highlighted risks of separating newborns from mothers during COVID-19 pandemic
On Mar. 16, 2021, research from the World Health Organization (WHO) and partners showed that the COVID-19 pandemic…
-
TGen study predicted changing Lyme disease habitat across the West Coast
On Mar. 16, 2021, TGen announced a study that suggested ecosystems suitable for harboring ticks that carry debilitating…
-
Moderna announced participants dosed in phase 2/3 study of COVID-19 vaccine in pediatric population
On Mar. 16, 2021, Moderna announced that the first participants had been dosed in the Phase 2/3 study,…
-
ImmunityBio announced positive interim phase I safety data of hAd5 T-cell COVID-19 vaccine candidate
On Mar. 15, 2021, ImmunityBio announced it had met the safety requirements for the first 12 participants in…
-
First participants dosed in Moderna phase 1 study evaluating mRNA-1283 next generation COVID-19 vaccine
On Mar. 15, 2021, Moderna announced that the first participants had been dosed in the Phase 1 study…
-
Biotechnology | CDC | COVID-19 | Diagnostics | Genomics | Infectious Disease | Vaccine
Fulgent Genetics awarded contract from CDC to study variants of COVID-19 virus
On Mar. 15, 2021, Fulgent Genetics announced that the U.S. Centers for Disease Control and Prevention had awarded…
-
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Therapeutics | Vaccine | WHO
WHO added Janssen vaccine to list of safe and effective emergency tools against COVID-19
On Mar. 12, 2021, The World Health Organization (WHO) listed the COVID-19 vaccine Ad26.COV2.S, developed by Janssen (Johnson…
-
Abbott announced Pandemic Defense Coalition to help prevent future pandemics
On Mar. 11, 2021, Abbott announced the formation of the Abbott Pandemic Defense Coalition, a first-of-its-kind global scientific…
-
Rigel announced completion of patient enrollment for phase 2 trial of fostamatinib in hospitalized COVID-19 patients
On Mar. 11, 2021, Rigel Pharma announced the completion of patient enrollment in a multi-center Phase 2 clinical trial to…
-
ImmunityBio announced novel ACE2 decoy COVID-19 therapeutic that showed high binding to SARS-CoV-2 variants
On Mar. 11, 2021, ImmunityBio announced it was developing a novel hAd5 ACE2 Decoy therapeutic vaccine to neutralize…
-
Altimmune expanded AdCOVID manufacturing collaboration with Lonza
On Mar. 11, 2021, Altimmune announced that it had expanded its previously-announced AdCOVID manufacturing collaboration with Lonza. Under the…
